SCHEMBL496698

SCHEMBL496698

O=S(=O)(O)CC1CCCN1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.39
KMT2A Q03164 3/20 0.36
INPP5A Q14642 1/20 0.35
CYP2D6 P10635 2/20 0.34
MEN1 O00255 2/20 0.34
LMNA P02545 2/20 0.34
TP53 P04637 2/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
TSHR P16473 1/20 0.34
MLNR O43193 1/20 0.34
ABCB11 O95342 1/20 0.34
EGFR P00533 1/20 0.34
FYN P06241 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
HTR1A P08908 1/20 0.34
CHRM5 P08912 1/20 0.34
ADRA2A P08913 1/20 0.34
ADORA3 P0DMS8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27722349 1.00 FDPS (0.39) FDPSKMT2AINPP5ACYP2D6MEN1
Sulfuric Acid SCHEMBL28199660 0.79 FDPS (0.44) FDPSKMT2ACYP2D6MEN1LMNA
SCHEMBL1870883 0.78 KMT2A (0.36) FDPSKMT2ACYP2D6MEN1LMNA
SCHEMBL20762013 0.78 APLNR (0.36) FDPSKMT2ACYP2D6MEN1LMNA
SCHEMBL6393331 0.78 KMT2A (0.36) FDPSKMT2ACYP2D6MEN1LMNA
SCHEMBL25040341 0.78 APLNR (0.36) FDPSKMT2ACYP2D6MEN1LMNA
SCHEMBL4723842 0.78 KMT2A (0.36) FDPSKMT2ACYP2D6MEN1LMNA
Hydrochloric Acid SCHEMBL20744622 0.77 KMT2A (0.38) FDPSKMT2ACYP2D6MEN1LMNA
SCHEMBL1709329 0.74
SCHEMBL512365 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2578577-A1 Sulfonyl esters of tetrahydrocannabinol and derivatives thereof Albany Molecular Research, Inc. (US) 2013-04-10 EP claimed
US-7674922-B2 Process for production of delta-9-tetrahydrocannabinol ALBANY MOLECULAR RESEARCH, INC. (US) 2010-03-09 US claimed
EP-1928853-A2 PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL AMR Technology, Inc. (US) 2008-06-11 EP claimed
US-20070093665-A1 Process for production of delta-9- tetrahydrocannabinol AMR TECHNOLOGY, INC. (US) 2007-04-26 US claimed
WO-2007041167-A2 PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL AMR TECHNOLOGY, INC. (US) 2007-04-12 WO claimed
EP-0467856-B1 Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases NIPPON ZOKI PHARMACEUTICAL CO (JP) 1997-03-19 EP claimed
EP-0467856-A2 Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1992-01-22 EP claimed
US-10265644-B2 Enantioselective zwitterionic ion-exchange material UNIVERSITAET WIEN (AT) 2019-04-23 US disclosed
US-10265644-B2 Enantioselective zwitterionic ion-exchange material UNIVERSITAET WIEN (AT) 2019-04-23 US disclosed
EP-2276567-B1 ENANTIOSELECTIVE ZWITTERIONIC ION-EXCHANGE MATERIAL UNIV WIEN (AT) 2019-04-10 EP disclosed
US-20160193547-A1 ENANTIOSELECTIVE ZWITTERIONIC ION-EXCHANGE MATERIAL UNIVERSITAET WIEN (AT) 2016-07-07 US disclosed
US-20160193547-A1 ENANTIOSELECTIVE ZWITTERIONIC ION-EXCHANGE MATERIAL UNIVERSITAET WIEN (AT) 2016-07-07 US disclosed
US-20160193547-A1 ENANTIOSELECTIVE ZWITTERIONIC ION-EXCHANGE MATERIAL UNIVERSITAET WIEN (AT) 2016-07-07 US disclosed
US-7244764-B2 Methods and compositions for treating amyloid-related diseases NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-07-17 US disclosed
US-7244764-B2 Methods and compositions for treating amyloid-related diseases NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-07-17 US disclosed
US-20070093665-A1 Process for production of delta-9- tetrahydrocannabinol AMR TECHNOLOGY, INC. (US) 2007-04-26 US disclosed
WO-2007041167-A2 PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL AMR TECHNOLOGY, INC. (US) 2007-04-12 WO disclosed
EP-0467856-B1 Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases NIPPON ZOKI PHARMACEUTICAL CO (JP) 1997-03-19 EP disclosed
US-5430052-A Protective effect against myocardial disorders caused by calcium ion overload; antiischemic agents; remedy for heart failure, angina pectoris NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1995-07-04 US disclosed
EP-0467856-A2 Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1992-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093665-A1 Process for production of delta-9- tetrahydrocannabinol CNR2, CNR1, HRH4 FDPS 794/4885KMT2A 2043/4885INPP5A 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.